Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceti… (NCT07226557) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation
United States5,000 participantsStarted 2025-01-01
Plain-language summary
This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a best available therapy treatment strategy.
Who can participate
Age range18 Years – 100 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Hospitalized adults (≥ 18 years of age)
* Carbapenem resistant A. baumannii-calcoaceticus complex clinical culture
* Antimicrobial agent with possible in vitro activity against carbapenem resistant A. baumannii-calcoaceticus complex initiated in the time frame of 2 days before culture collection until 2 days following first available antibiotic susceptibility test result being made available
Exclusion Criteria:
* Patients with no antibiotic susceptibility testing
* Patients with only A. baumannii infection diagnosed by rapid diagnostic tests (i.e., multiplex polymerase chain reaction)
* Initiation of antimicrobial agent outside of selected time frame (i.e., 2 days before culture collection until 2 days after first available antibiotic susceptibility test result was made available)
What they're measuring
1
Mortality
Timeframe: During inpatient admission
Trial details
NCT IDNCT07226557
SponsorNational Institutes of Health Clinical Center (CC)